Activated T Cells for Brain Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a treatment where a patient's own immune cells are enhanced to better fight cancer. It aims to find out if this treatment is safe and how well it works for cancer patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the treatment with activated T cells generally safe for humans?
Studies on activated T cells for brain cancer have shown that the treatment is generally safe, with most patients experiencing only mild side effects like flu-like symptoms. These studies suggest that the therapy is feasible and associated with minimal toxicity, although more research is needed to fully understand its safety.12345
How does the treatment Activated Autologous T Cells differ from other treatments for brain cancer?
Activated Autologous T Cells are unique because they involve using a patient's own immune cells, which are collected, activated, and then reinfused to specifically target and attack brain tumor cells. This personalized approach contrasts with traditional treatments like chemotherapy and radiation, which are less targeted and can affect healthy cells as well.12678
What data supports the effectiveness of the treatment Activated Autologous T Cells for brain cancer?
Research shows that using activated T cells, which are a type of immune cell, can help fight brain tumors. In some studies, patients with brain cancer who received this treatment had their tumors shrink, and a few remained disease-free for years. This suggests that the treatment might be effective, but more studies are needed to confirm its benefits.1291011
Who Is on the Research Team?
Jeremy D. Rudnick
Principal Investigator
Cedars-Sinai Medical Center
Are You a Good Fit for This Trial?
This trial is for individuals with recurrent glioblastoma who are HLA-A1 and HLA-A2 positive and have had a complete resection of their tumor. It's not suitable for those with HIV/AIDS, hepatitis B or C, allergies to DMSO or gentamicin, significant heart or lung disease, or active infections needing treatment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive activated autologous T cells to assess safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are assessed for overall response rate and tumor stem cell antigen expression
What Are the Treatments Tested in This Trial?
Interventions
- Activated Autologous T Cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jeremy Rudnick, M.D
Lead Sponsor
Kairos Pharma
Collaborator